Sana Biotechnology Inc - Asset Resilience Ratio
Sana Biotechnology Inc (SANA) has an Asset Resilience Ratio of 15.95% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SANA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Sana Biotechnology Inc's Asset Resilience Ratio has changed over time. See SANA net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sana Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Sana Biotechnology Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $66.51 Million | 15.95% |
| Total Liquid Assets | $66.51 Million | 15.95% |
Asset Resilience Insights
- Good Liquidity Position: Sana Biotechnology Inc maintains a healthy 15.95% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Sana Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Sana Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Sana Biotechnology Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Sana Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.95% | $66.51 Million | $416.89 Million | +10.98pp |
| 2024-12-31 | 4.98% | $24.93 Million | $501.02 Million | -7.70pp |
| 2023-12-31 | 12.68% | $71.68 Million | $565.30 Million | -17.37pp |
| 2022-12-31 | 30.05% | $247.20 Million | $822.72 Million | +3.66pp |
| 2021-12-31 | 26.38% | $297.97 Million | $1.13 Billion | -8.32pp |
| 2020-12-31 | 34.71% | $253.46 Million | $730.30 Million | +20.51pp |
| 2019-12-31 | 14.20% | $58.95 Million | $415.19 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $34.33 Million | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more